35 completed, 15 recruiting, 9 terminated, 6 unknown. 29 Phase 2, 23 Phase 1, 4 Not applicable, 4 Phase 3, 3 Phase 4.
Follow Renal Cell Cancer: new trials by email Literature Review of Renal Cell Cancer trials Research Report on Renal Cell Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC WGI-0301, Nivolumab (240 mg) - Hepato Cellular Carcinoma (HCC), Renal Cell Cancer | Phase 2 | Not yet recruiting | Zhejiang Haichang Biotech Co., Ltd. | 230 | 2026-06-01 | 2026-03-27 |
| Study of the Prognostic Impact of CD44 on Renal Cell Carcinoma Renal Cell Cancer | Not yet recruiting | Assiut University | 77 | 2025-11-01 | 2025-01-14 | |
| Contrast-enhanced Ultrasound and Super-resolution Imaging Predict Renal Function Outcome After Nephrectomy Nephrectomy, Renal Cell Cancer | Recruiting | Jinling Hospital, China | 285 | 2025-09-01 | 2025-12-19 | |
| Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations. Deferred Cytoreductive Nephrectomy + medical treatment, Radiotherapy + medical treatment, Medical therapy - Renal Cell Cancer, Kidney Neoplasm | Phase 4 | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 409 | 2025-06-15 | 2025-07-03 |
| Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma Nivolumab, Cabozantinib - Kidney Cancer, Renal Cell Cancer | Phase 4 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 50 | 2025-05-16 | 2025-09-24 |
| Using 3D Kidney Model Based on Artificial Intelligence to Assist Partial Nephrectomy: A Prospective Validation Study an AI-based real-time image-guided kidney model system - Renal Cell Cancer | Not applicable | Recruiting | Shao Pengfei | 232 | 2025-05-01 | 2025-06-13 |
| Prehabilitation Prior to Surgery for Kidney Tumors Prehabilitation - Renal Cancer, Renal Cell Cancer | Not applicable | Active not recruiting | Herlev and Gentofte Hospital | 60 | 2025-01-21 | 2026-09-02 |
| Optimising Renal Tumour Management Through Artificial Intelligence Modules Renal Neoplasms, Pathology | Recruiting | Shao Pengfei | 2100 | 2025-01-01 | 2025-03-19 | |
| The Value of a Convolutional Neural Network-Based Renal Artery Perfusion Model in Predicting Renal Function After Partial Nephrectomy: A Prospective Study Renal Cell Cancer | Recruiting | Shao Pengfei | 300 | 2025-01-01 | 2025-04-17 | |
| Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma Follow-up study of the treated cohort - Neoplasms, Kidney Neoplasms | Recruiting | Jinling Hospital, China | 39 | 2024-09-01 | 2025-12-05 | |
| A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy Alintegimod, Ipilimumab, Nivolumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | 7 Hills Pharma, LLC | 126 | 2024-08-23 | 2026-04-13 |
| A Study of IBI363 in Subjects with Advanced Solid Malignancies IBI363 - Melanoma, Non-small Cell Lung Cancer | Phase 2 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 178 | 2024-04-08 | 2024-12-19 |
| TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma TT-10, TT-4 - Renal Cell Cancer, Castrate Resistant Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Portage Biotech | 35 | 2023-06-23 | 2026-09-15 |
| Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome Urological Malignancies, Prostate Cancer | Recruiting | Yonsei University | 3000 | 2022-12-19 | 2023-01-31 | |
| Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib Axitinib, Pembrolizumab - Renal Cell Cancer | Phase 2 | Withdrawn | University of Oklahoma | 2022-06-01 | 2022-08-02 | |
| A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland. Renal Cell Cancer, Renal Cell Carcinoma | Completed | Pfizer | 1112 | 2022-05-02 | 2024-10-01 | |
| Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer Modi-1 Moditope, Pembrolizumab, MicronJet600™ microneedle device (NanoPass) - Triple Negative Breast Cancer, Renal Cell Cancer | Phase 1 / Phase 2 | Recruiting | Scancell Ltd | 168 | 2022-04-07 | 2025-09-17 |
| Study of PF-07263689 in Participants With Selected Advanced Solid Tumors PF-07263689, Sasanlimab - Renal Cell Cancer, Melanoma | Phase 1 | Terminated | Pfizer | 13 | 2021-10-20 | 2024-04-12 |
| Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer Low Dose Rate Brachytherapy (LDR), Standard-of-Care Immunotherapy - Cutaneous Malignant Melanoma, Renal Cell Cancer | Phase 1 | Active not recruiting | Case Comprehensive Cancer Center | 5 | 2021-05-27 | 2026-05-05 |
| Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma Cabometyx - Renal Cell Cancer | Phase 2 | Unknown | Asan Medical Center | 201 | 2021-03-01 | 2021-01-19 |
Showing 20 of 75. Sign in to see all of them.
Carcinoma, Renal Cell (75) · Kidney Neoplasms (19) · Carcinoma, Non-Small-Cell Lung (10) · Colorectal Neoplasms (9) · Melanoma (8) · Breast Neoplasms (7) · Neoplasms (5) · Prostatic Neoplasms (5) · Urinary Bladder Neoplasms (5) · Ovarian Neoplasms (4) · Pancreatic Neoplasms (4) · Kidney Diseases (3) · Liver Neoplasms (3) · Sarcoma (3) · Triple Negative Breast Neoplasms (3)
Adenocarcinoma (75) · Female Urogenital Diseases and Pregnancy Complications (75) · Neoplasms by Histologic Type (75) · Neoplasms by Site (75) · Neoplasms, Glandular and Epithelial (75) · Carcinoma (74) · Female Urogenital Diseases (74) · Male Urogenital Diseases (74) · Urogenital Diseases (74) · Urogenital Neoplasms (74) · Urologic Diseases (74) · Urologic Neoplasms (74) · Kidney Diseases (72) · Neoplasms (70) · Kidney Neoplasms (56)
Bevacizumab (7) · Sunitinib (6) · Interferon alpha-2 (5) · Nivolumab (4) · pembrolizumab (4) · temsirolimus (4) · Axitinib (3) · Capecitabine (2) · Cyclophosphamide (2) · Sorafenib (2) · aldesleukin (2) · avelumab (2) · cabozantinib (2) · ciforadenant (2) · fludarabine (2)
Hoffmann-La Roche (6) · Pfizer (4) · M.D. Anderson Cancer Center (3) · National Cancer Institute (NCI) (3) · Radboud University Medical Center (3) · Shao Pengfei (3) · Case Comprehensive Cancer Center (2) · Corvus Pharmaceuticals, Inc. (2) · Genentech, Inc. (2) · Hadassah Medical Organization (2) · Jinling Hospital, China (2) · Washington University School of Medicine (2) · Yonsei University (2) · 7 Hills Pharma, LLC (1) · AHS Cancer Control Alberta (1)
United States (29) · Germany (8) · Netherlands (8) · China (7) · United Kingdom (7) · Canada (5) · Italy (5) · Australia (4) · France (4) · South Korea (4) · Austria (3) · Finland (3) · Israel (3) · Russia (3) · Belgium (2)
James C Yang, M.D. (2) · Nizar M. Tannir, MD (2) · Abhishek Tripathi, MD (1) · Arnulf Stenzl, Prof. (1) · Brent O'Carrigan (1) · Brian Rini (1) · Christian Ottensmeier, MD (1) · Cliff P Connery, MD (1) · Cynthia Lynch, MD (1)
PMID 33947608, PMID 35166465, PMID 37146227, PMID 37526095, PMID 22704310, PMID 23803225, PMID 25902855, PMID 25915780, PMID 25944802, PMID 26106073, PMID 26335224, PMID 26541586, PMID 28291390, PMID 28548889, PMID 28558150, PMID 28679770, PMID 29530667, PMID 30711970, PMID 30779531, PMID 30786188, PMID 31189049, PMID 31668633, PMID 32339648, PMID 32859933, PMID 32895571, PMID 32946924, PMID 33741442, PMID 33901870, PMID 34794412, PMID 35239416, PMID 35728046, PMID 36576173, PMID 36600561, PMID 37104931, PMID 37852850, PMID 37941979, PMID 38897136, PMID 38981998, PMID 39706335, PMID 39886142, PMID 40657894, PMID 41369900, PMID 41592385, PMID 42433301
2015 (2), 2004 (1), 2014 (1), R01CA141521 (1), R01CA249909 (1)